Dermira Inc. (DERM) Plunged To A New Low After Phase 3 Study Failed

Dermira Inc. (DERM) announced Monday morning that olumacostat glasaretil did not meet the co-primary endpoints in its two Phase 3 studies.

from RTT - Before the Bell http://ift.tt/2H9Anqs
via IFTTT